A multi-centre, open label, phase II study of the safety, efficacy and pharmacokinetic (PK) profile of CAP-232 administered through continuous intravenous infusion in patients with metastatic kidney cancer
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2012
At a glance
- Drugs TLN 232 (Primary)
- Indications Renal cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Caprion Pharmaceuticals; Thallion Pharmaceuticals
- 14 Jul 2008 Actual patient number 10 is updated as reported by ClinicalTrials.gov.
- 14 Jul 2008 Actual end date is now 1 Mar 2008 as reported by ClinicalTrials.gov.
- 14 Jul 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.